TW202003004A - Use of Antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease - Google Patents
Use of Antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- TW202003004A TW202003004A TW107117897A TW107117897A TW202003004A TW 202003004 A TW202003004 A TW 202003004A TW 107117897 A TW107117897 A TW 107117897A TW 107117897 A TW107117897 A TW 107117897A TW 202003004 A TW202003004 A TW 202003004A
- Authority
- TW
- Taiwan
- Prior art keywords
- antrodia camphorata
- mycelium
- active substance
- item
- patent application
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 36
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 23
- 241001486992 Taiwanofungus camphoratus Species 0.000 title claims description 80
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 7
- 241000723346 Cinnamomum camphora Species 0.000 claims description 6
- 229960000846 camphor Drugs 0.000 claims description 6
- 229930008380 camphor Natural products 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000003570 air Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract 3
- 239000012887 cigarette smoke extract Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 241000723347 Cinnamomum Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000082946 Tarchonanthus camphoratus Species 0.000 description 1
- 235000005701 Tarchonanthus camphoratus Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本發明關於一種樟芝菌絲體活性物質的製備方法及其用途。具體來說,關於製備一種用於改善慢性阻塞性肺病的樟芝菌絲體活性物質,以及其在食品或醫藥品中的用途。The invention relates to a preparation method and application of active substances of Antrodia camphorata mycelium. Specifically, it relates to the preparation of an active substance of Antrodia camphorata mycelia for improving chronic obstructive pulmonary disease, and its use in food or medicine.
慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease,簡稱COPD) 目前居全球死亡原因的第4位,是一種常見、多發、高致殘率和高致死率的慢性呼吸系統疾病。全世界慢性阻塞性肺病的患者有超過三億人。Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world. It is a common, frequent, high disability rate and high mortality rate of chronic respiratory diseases. There are more than 300 million people with chronic obstructive pulmonary disease worldwide.
吸菸是導致COPD的主要原因,然近年因我國機車、汽車的排廢氣以及工業上發電與燃油燃煤的使用增加,導致Particulate Matter (PM) 2.5 的空氣汙染上升,更加重此一疾病的發生。長期暴露在污染的環境下,會使肺部產生發炎反應,導致氣流通道變窄而產生肺組織功能障礙。Smoking is the main cause of COPD. However, in recent years, due to the increased emissions of locomotives and automobiles in China and the increased use of power generation and fuel coal in industry, the air pollution of Particulate Matter (PM) 2.5 has increased, and this disease is more important. . Long-term exposure to a polluted environment can cause an inflammatory reaction in the lungs, resulting in narrowing of airflow channels and resulting in lung tissue dysfunction.
COPD的治療方式目前包含戒菸、肺康復治療、吸入性支氣管擴張藥、使用皮質類固醇、長期供氧或進行肺移植等。2015年最新通過的新藥係合併過去兩種使用於COPD的肌肉鬆弛劑,截至目前仍未有突破性的新藥發展。因此,研究有效治療慢性阻塞性肺病的方法仍是重要的發展方向。COPD treatment methods currently include smoking cessation, lung rehabilitation, inhaled bronchodilators, corticosteroid use, long-term oxygen supply, or lung transplantation. The newly approved new drug series in 2015 merged the two muscle relaxants used in COPD in the past, and so far there has been no breakthrough new drug development. Therefore, research on effective treatment of chronic obstructive pulmonary disease is still an important development direction.
樟芝(Antrodia cinnamomea ),又稱為樟菇、樟菰、樟內菇、牛樟菇、牛樟芝、紅樟、紅樟芝,只生長於台灣山區海拔450-1500公尺間的牛樟樹幹腐朽之心材內壁或枯死倒伏之牛樟木材陰暗潮濕之表面,屬於台灣國寶級的珍貴藥用真菌。目前仍缺乏樟芝對改善慢性阻塞性肺病之研究。 Antrodia cinnamomea ( Antrodia cinnamomea ), also known as camphor, camphor, camphor mushroom, cinnamomum , cinnamomea , red camphor, red camphor, only grows in the decayed trunk of Antrodia camphorata at an altitude of 450-1500 meters in the mountainous area of Taiwan The inner wall of the heartwood or the dark and damp surface of the withered and fallen camphor wood belongs to the precious medicinal fungi of Taiwan national treasure level. At present, there is still a lack of research on Zhangzhi to improve chronic obstructive pulmonary disease.
本發明之提供一種樟芝菌絲體活性物質及其製備方法,其可用於製備具改善慢性阻塞性肺病之組合物。相較於一般西藥及治療方法,本發明揭露的液態發酵樟芝菌絲體活性物質的製備方法更為安全、簡便,製成之樟芝菌絲體活性物質更天然、安全,並可有效改善COPD。The invention provides an active substance of Antrodia camphorata mycelium and a preparation method thereof, which can be used for preparing a composition with improved chronic obstructive pulmonary disease. Compared with the general western medicine and the treatment method, the preparation method of the liquid fermented Antrodia camphorata mycelium active substance disclosed by the present invention is safer and simpler, and the prepared Antrodia camphorata mycelium active substance is more natural and safe, and can be effectively improved COPD.
根據本發明之一實施例,提供一種樟芝菌絲體活性物質用於製備改善慢性阻塞性肺病之組合物的用途,其中樟芝菌絲體活性物質係以下列步驟製備而成:According to an embodiment of the present invention, there is provided a use of an active substance of Antrodia camphorata mycelium for preparing a composition for improving chronic obstructive pulmonary disease, wherein the active substance of Antrodia camphorata mycelium is prepared by the following steps:
(a)取樟芝菌絲體(Antrodia cinnamomea )於平板培養基上,於15-30℃之溫度下培養4-10天;(a) Take Antrodia cinnamomea on a plate medium and incubate at a temperature of 15-30℃ for 4-10 days;
(b)將步驟(a)培養後之樟芝菌絲體接種至燒瓶內,於15-30℃、pH 2-6之環境培養3-14天;(b) Inoculate the Antrodia camphorata mycelium cultured in step (a) into the flask, and cultivate it for 3-14 days in an environment of 15-30°C and pH 2-6;
(c)將步驟(b)培養後之樟芝菌絲體接種於發酵槽內,於15-30℃、pH 2-6之環境下攪拌培養3-21天,形成含有樟芝菌絲體活性物質之樟芝菌絲體發酵液。(c) Inoculate the mycelium of Antrodia camphorata after cultivation in step (b) in a fermentation tank, and stir and cultivate for 3-21 days at an environment of 15-30°C and pH 2-6 to form an activity containing Antrodia camphorata mycelia Substance of Antrodia camphorata mycelium fermentation broth.
一實施例中,製備樟芝菌絲體活性物質的步驟更包括步驟(d):將樟芝菌絲體發酵液冷凍乾燥後磨粉,形成含有樟芝菌絲體活性物質之樟芝菌絲體凍乾粉。In one embodiment, the step of preparing the active substance of Antrodia camphorata mycelia further includes step (d): freeze-drying the fermentation broth of Antrodia camphorata mycelia and grinding it to form antrodia camphorata mycelium containing the active substance of Antrodia camphorata mycelia Body lyophilized powder.
一實施例中,製備樟芝菌絲體活性物質的步驟更包括步驟(e):將樟芝菌絲體凍乾粉以至少一溶劑萃取,形成含有樟芝菌絲體活性物質之樟芝菌絲體萃取液。In one embodiment, the step of preparing the active substance of Antrodia camphorata mycelium further includes step (e): extracting the freeze-dried powder of Antrodia camphorata mycelium with at least one solvent to form Antrodia camphorata containing the active substance of Antrodia camphorata mycelium Silk extract.
一實施例中,製備樟芝菌絲體活性物質的步驟更包括步驟(f):將樟芝菌絲體萃取液乾燥,以獲得樟芝菌絲體活性物質。In one embodiment, the step of preparing the active substance of Antrodia camphorata mycelia further includes step (f): drying the extract of the mycelium of Antrodia camphorata to obtain the active substance of the mycelium of Antrodia camphorata.
一實施例中,步驟(e)中的溶劑係選自水或醇類。In one embodiment, the solvent in step (e) is selected from water or alcohols.
一實施例中,當步驟(e)之溶劑為水時,樟芝菌絲體活性物質的有效濃度介於 0.25-1 mg/ml。In one embodiment, when the solvent in step (e) is water, the effective concentration of the active substance of Antrodia camphorata mycelium is between 0.25-1 mg/ml.
一實施例中,當步驟(e)之該溶劑為醇類時,樟芝菌絲體活性物質的有效濃度介於25-100 μg/ml。In one embodiment, when the solvent in step (e) is an alcohol, the effective concentration of the active substance of Antrodia camphorata mycelium is between 25-100 μg/ml.
一實施例中,上述步驟(b)之燒瓶培養為震盪培養,且轉速為110-130 rpm。In one embodiment, the flask culture in the above step (b) is shaking culture, and the rotation speed is 110-130 rpm.
一實施例中,步驟(c)中的發酵槽進一步通入一氣體,此氣體包括空氣、氧氣、二氧化碳、氦氣或其組合,發酵槽的槽壓為0.5-1.0 kg/cm2 且通氣速率為0.01-1.5VVM。In one embodiment, the fermentation tank in step (c) is further fed with a gas, the gas includes air, oxygen, carbon dioxide, helium, or a combination thereof, the fermentation tank has a tank pressure of 0.5-1.0 kg/cm 2 and aeration rate It is 0.01-1.5VVM.
一實施例中,所述組合物為醫藥組合物,此醫藥組合物進一步包含藥學上可接受之載劑、賦形劑、稀釋劑或輔劑。In one embodiment, the composition is a pharmaceutical composition, and the pharmaceutical composition further includes a pharmaceutically acceptable carrier, excipient, diluent or adjuvant.
一實施例中,所述組合物為食品添加劑。In one embodiment, the composition is a food additive.
為使本發明之上述及其它方面更為清楚易懂,下文特舉實施例,並配合所附圖式詳細說明。In order to make the above and other aspects of the present invention clearer and more understandable, the embodiments are specifically described below in conjunction with the accompanying drawings.
實施例一 樟芝菌絲體培養Example 1 Antrodia camphorata mycelium culture
本實施例採用之樟芝菌絲體(Antrodia cinnamomea )係購自財團法人食品工業發展研究所(FIRDI)生物資源保存及研究中心(BCRC,前稱CCRC),編號為CCRC-35396。然而,可用於本發明的樟芝品種並不限定於此單獨一種,其更可包括BCRC編號35396、35398、35716、36401、36711、36795、37848、37849、37850、37889、37890、37891、37893、37894、37941或及其他生物材料寄存資料庫的樟芝菌種,本發明並不對其限制。The Antrodia cinnamomea used in this example was purchased from the Biological Resource Preservation and Research Center (BCRC, formerly CCRC) of the Food Industry Development Institute (FIRDI) of the consortium, and the number is CCRC-35396. However, the Antrodia camphorata varieties that can be used in the present invention are not limited to this single one, but can also include BCRC numbers 35396, 35398, 35716, 36401, 36711, 36795, 37848, 37849, 37850, 37889, 37890, 37891, 37893, The species of Antrodia camphorata strains of 37894, 37941 or other biological material storage databases are not limited by the present invention.
(1)平板培養:將樟芝菌絲體接種於平板上,於15-30℃下培養4-10天(本實施例中,係於25℃下培養7天)。平板培養基的成份可包含馬鈴薯糊精培養基(Potato Dextrose Agar, PDA)、碳源及氮源,並無特別限制。(1) Plate culture: Antrodia camphorata mycelium is inoculated on the plate and cultivated at 15-30°C for 4-10 days (in this example, it is cultivated at 25°C for 7 days). The components of the plate medium may include potato dextrin medium (Potato Dextrose Agar, PDA), carbon source and nitrogen source, and are not particularly limited.
(2)燒瓶培養:刮取(1)平板上之菌絲體接種於燒瓶中,並以15-30℃、pH 2-6及轉速110-130 rpm的條件震盪培養3-14天(本實施例中,於25℃、pH 5、轉速120 rpm之下震盪培養10天)。此震盪培養係以下表1所示之培養基進行培養。(2) Flask culture: scrape (1) inoculate the mycelium on the plate into the flask, and culture with shaking at 15-30°C, pH 2-6 and rotation speed 110-130 rpm for 3-14 days (this implementation In the example, it was cultured with shaking at 25°C, pH 5, and rotation speed of 120 rpm for 10 days). This shaking culture was carried out with the medium shown in Table 1 below.
表1 培養基配方
上述培養基配方中,黃豆粉及肉桂粉為綜合性碳氮源,其可選自穀類(如:麥粉)或豆類(如:黃豆粉、綠豆粉、大豆粉、肉桂粉等);醣類可為葡萄糖、果糖、麥芽糖、蔗糖等;無機鹽類可為硫酸鎂、磷酸氫二鉀、磷酸二氫鉀、硫酸鐵等。特別說明的是,表1培養基配方僅為其中一種範例,使用時成份可依需求調整,或搭配市售培養基使用,並無特別限制。In the above medium formula, soybean powder and cinnamon powder are comprehensive carbon and nitrogen sources, which can be selected from cereals (such as wheat flour) or beans (such as soybean powder, mung bean powder, soybean powder, cinnamon powder, etc.); sugars can be It is glucose, fructose, maltose, sucrose, etc.; inorganic salts can be magnesium sulfate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, ferric sulfate, etc. In particular, the formula of the medium in Table 1 is just one example, and the ingredients can be adjusted according to needs or used with commercially available medium without special restrictions.
(3)發酵槽培養:將(2)中燒瓶培養的菌絲體接種於發酵槽內,以15-30 ℃、槽壓0.5-1.0 kg/cm2 、pH 2-6及攪拌速度50-150 rpm條件下,以0.1-1.5 VVM的通氣速率培養3-21天,形成一樟芝菌絲體發酵液(本實施例中,係在25℃、槽壓0.5 kg/cm2 、pH 4,攪拌速度80 rpm及1.0 VVM(空氣)的條件下,培養14天),即得樟芝菌絲體發酵液。發酵槽培養使用之培養基可與步驟(2)燒瓶培養使用之培養基相同。此樟芝菌絲體發酵液內即含本發明之樟芝菌絲體活性物質。樟芝菌絲體發酵液可進一步藉由冷凍乾燥步驟製備為樟芝菌絲體發酵液凍乾粉;(3) Fermentation tank culture: inoculate the mycelium cultured in the flask in (2) into the fermentation tank at 15-30 ℃, tank pressure 0.5-1.0 kg/cm 2 , pH 2-6 and stirring speed 50-150 Under the condition of rpm, incubate at aeration rate of 0.1-1.5 VVM for 3-21 days to form a fermentation liquid of Antrodia camphorata mycelium (in this example, it was stirred at 25°C, tank pressure 0.5 kg/cm 2 , pH 4 and stirred Under the conditions of speed 80 rpm and 1.0 VVM (air), culture for 14 days), the fermentation liquid of Antrodia camphorata mycelium is obtained. The culture medium used for fermentation tank culture may be the same as the culture medium used for flask culture in step (2). The Antrodia camphorata mycelium fermentation liquid contains the active substance of Antrodia camphorata mycelium according to the present invention. The fermentation liquid of Antrodia camphorata mycelium can be further prepared as a freeze-dried powder of the fermentation liquid of Antrodia camphorata mycelium by a freeze-drying step;
(4)萃取物製備:將樟芝菌絲體發酵液凍乾粉分為兩份,分別加入20倍重量之蒸餾水及乙醇進行萃取。以水為溶劑的萃取物以溫度100℃加熱三十分鐘,待冷卻後離心取上清液,經冷凍乾燥法進行乾燥得樟芝發酵菌絲體水萃物。以乙醇為溶劑的萃取物,以超音波震盪1小時,離心後取上清液,將上清液經減壓濃縮得樟芝發酵菌絲體醇萃物;(4) Preparation of extract: The lyophilized powder of the fermentation solution of Antrodia camphorata mycelium is divided into two parts, and 20 times the weight of distilled water and ethanol are added to extract. The extract using water as a solvent is heated at a temperature of 100°C for thirty minutes. After cooling, the supernatant is taken by centrifugation and dried by freeze-drying to obtain an aqueous extract of fermented mycelia of Antrodia camphorata. The ethanol-extracted extract was shaken with ultrasound for 1 hour. After centrifugation, the supernatant was taken, and the supernatant was concentrated under reduced pressure to obtain an alcohol extract of Antrodia camphorata fermentation mycelium;
經由萃取步驟,可取得含較高濃度之樟芝菌絲體活性物質的水萃物及醇萃物。樟芝菌絲體活性物質的態樣包含樟芝菌絲體發酵液(菌絲體與澄清液)、發酵液凍乾粉、水萃物、醇萃物、水萃物及醇萃物之混合物或其他劑型。以下實施例二中,係以水萃物及醇萃物作為樟芝菌絲體活性物質態樣。實施例二 樟 芝菌絲體水萃物及醇萃物改善 COPD 之分析 Through the extraction step, water extracts and alcohol extracts containing higher concentrations of active substances of Antrodia camphorata mycelium can be obtained. The active substances of Antrodia camphorata mycelia include the fermentation liquid of mycelium of Antrodia camphorata (mycelium and clarified liquid), lyophilized powder of fermentation broth, water extract, alcohol extract, water extract and mixture of alcohol extract Or other dosage forms. In the second embodiment below, the water extract and the alcohol extract are used as the active substance of Antrodia camphorata mycelium. Example 2 Analysis of water extract and alcohol extract of Antrodia camphorata mycelia to improve COPD
目前已有實驗利用香菸煙霧萃取物(Cigarette smoke extract,CSE)及人類肺癌上皮細胞A549成功建立COPD模式。可參照Miaomiao Chen et al. (2015). Azithromycin attenuates cigarette smoke extract-induced oxidative stress injury in human alveolar epithelial cells.MOLECULAR MEDICINE REPORTS, 11: 3414-3422. 此篇論文,其以人類肺癌上皮細胞A549對CSE進行細胞存活率分析(MTT assay),用以評估抗生素Azithromycin對COPD的改善結果。CSE對肺泡上皮的損傷是慢性阻塞性肺病機制中的重要過程。 因此,若能抑制CSE對肺泡上皮的傷害即能達到改善慢性阻塞性肺病的效果。本實驗中亦以人類肺癌上皮細胞A549對CSE進行細胞存活率分析(MTT assay),評估樟芝菌絲體活性物質對COPD的改善結果。There have been experiments using Cigarette smoke extract (CSE) and human lung cancer epithelial cells A549 to successfully establish a COPD model. Refer to Miaomiao Chen et al. (2015). Azithromycin attenuates cigarette smoke extract-induced oxidative stress injury in human alveolar epithelial cells. MOLECULAR MEDICINE REPORTS , 11: 3414-3422. This paper uses human lung cancer epithelial cells A549 to CSE MTT assay was performed to evaluate the improvement of COPD by antibiotic Azithromycin. CSE damage to the alveolar epithelium is an important process in the mechanism of chronic obstructive pulmonary disease. Therefore, if it can suppress the damage of CSE to alveolar epithelium, it can achieve the effect of improving chronic obstructive pulmonary disease. In this experiment, the human lung cancer epithelial cell A549 was also used to perform cell survival analysis (MTT assay) on CSE to evaluate the improvement of COPD by the active substances of Antrodia camphorata mycelium.
(1)收集人類肺癌上皮A549細胞,調整細胞懸浮液濃度,以50,000-100,000/mL 密度植種於96孔盤內;(1) Collect human lung cancer epithelial A549 cells, adjust the concentration of the cell suspension, and plant them in 96-well dishes at a density of 50,000-100,000/mL;
(2)將(1)之96孔盤置於37℃、5% CO2 培養箱培養16-24小時後,以實施例一所獲得,不同劑量的樟芝菌絲體水萃物(0、0.25、0.5、1 mg/ml)及醇萃物(0、25、50、100 μg/ml)處理。樟芝菌絲體萃取物溶解於二甲基亞石楓(Dimethyl sulfoxide, DMSO)中,檢測時DMSO之濃度不超過0.1%以避免其毒性影響細胞生長;對照組處理0.1% DMSO,每個濃度進行三重複,結果置於37℃、5% CO2 培養箱培養24小時;(2) Place the 96-well plate of (1) in a 37°C, 5% CO 2 incubator for 16-24 hours, and obtain the water extract of Antrodia camphorata mycelium with different doses obtained in Example 1 (0, 0.25, 0.5, 1 mg/ml) and alcohol extracts (0, 25, 50, 100 μg/ml). Antrodia camphorata mycelium extract is dissolved in Dimethyl sulfoxide (DMSO), the concentration of DMSO does not exceed 0.1% when tested to avoid its toxicity affecting cell growth; the control group is treated with 0.1% DMSO, each concentration Three replicates were performed and the results were placed in a 37°C, 5% CO 2 incubator for 24 hours;
(3)上述(2)之結果先以400×g 離心10 min,移除上清液,再加入香菸煙霧萃取物CSE 12.5%誘導A549的細胞毒性,對照組不處理。接著置於37℃、5% CO2 培養箱培養6小時;(3) The result of (2) above was first centrifuged at 400 × g for 10 min, the supernatant was removed, and then the cigarette smoke extract CSE 12.5% was added to induce the cytotoxicity of A549, the control group was not treated. Then put it in 37℃, 5% CO 2 incubator for 6 hours;
(4)將(3)之上清液移除,每孔加入100 μl MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 溶液,於37℃反應 2小時後,終止培養,小心移除孔內MTT溶液;(4) Remove the supernatant from (3), add 100 μl MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution to each well, and react at 37℃ for 2 hours After that, stop the culture and carefully remove the MTT solution in the well;
(5)於(4)中每孔加入100 μl DMSO,震盪2 min,於570 nm 測定吸光值。此吸光度代表細胞還原MTT的能力(甲䐶的形成量),即粒線體的活性(活細胞數目)。於570 nm的吸光度越高,表示細胞存活率越高。(5) Add 100 μl DMSO to each well in (4), shake for 2 min, and measure the absorbance at 570 nm. This absorbance represents the ability of cells to reduce MTT (formation of formazan), that is, the activity of mitochondria (number of viable cells). The higher the absorbance at 570 nm, the higher the cell survival rate.
統計分析:實驗結果數據以平均值(Mean)±標準差(SD)表示。試驗數據以Student's t-test 統計分析其組間差異。若p < 0.05則視為具有統計上的顯著差異。Statistical analysis: The experimental result data is expressed as mean (Mean) ± standard deviation (SD). The test data was analyzed by Student's t-test statistics to analyze the differences between groups. If p <0.05, it is regarded as having statistically significant difference.
水萃物之實驗結果如第1圖及下表2所示。香菸煙霧萃取物CSE會誘導A549細胞毒性,造成細胞存活率下降。然而,加入樟芝發酵菌絲體水萃物可顯著性抑制細胞損傷,提昇存活率,且加入的濃度越高,存活率越高。採用本發明實施例一中的樟芝菌絲體水萃物具有改善COPD之作用,有效濃度介於0.5-1 mg/ml。The experimental results of the water extract are shown in Figure 1 and Table 2 below. Cigarette smoke extract CSE can induce A549 cytotoxicity, resulting in decreased cell survival rate. However, the addition of water extracts of fermented mycelia of Antrodia camphorata can significantly inhibit cell damage and improve survival rate, and the higher the concentration added, the higher the survival rate. Using the water extract of Antrodia camphorata mycelium in Example 1 of the present invention has the effect of improving COPD, and the effective concentration is between 0.5-1 mg/ml.
表2 樟芝菌絲體水萃物測試結果
醇萃物之實驗結果如第2圖及下表3所示。結果同樣表明,加入樟芝發酵菌本發明實施例一中的樟芝菌絲體醇萃物具有改善COPD之作用,有效濃度介於50-100 μg/ml。The experimental results of alcohol extracts are shown in Figure 2 and Table 3 below. The results also show that the addition of the Antrodia camphorata mycelium alcohol extract in the first embodiment of the present invention can improve the COPD, and the effective concentration is between 50-100 μg/ml.
表3 樟芝菌絲體醇萃物測試結果
本發明之樟芝活性物質經上述實驗,已證實具有改善COPD之作用。其可與藥學上可接受之載劑、賦形劑、稀釋劑或輔劑結合,製備醫藥組合物,亦可作為食品添加劑之用。The active substance of Antrodia camphorata according to the present invention has been confirmed to have the effect of improving COPD through the above experiments. It can be combined with pharmaceutically acceptable carriers, excipients, diluents or adjuvants to prepare pharmaceutical compositions and can also be used as food additives.
雖然本發明已用實施例揭露如上,然其並非用以限制本發明。本領域之通常知識者,於參酌以上教示後,當能對上述實施例的內容進行適當修改,而仍然能達到本案所主張之功效。因此,本發明的保護範圍應以其後所附之申請專利範圍修正本為準。Although the present invention has been disclosed as above using embodiments, it is not intended to limit the present invention. Those of ordinary knowledge in the art, after referring to the above teachings, should be able to make appropriate modifications to the content of the above-mentioned embodiments and still achieve the effect claimed in this case. Therefore, the scope of protection of the present invention shall be subject to the appended amendment to the scope of the patent application.
第1圖繪示樟芝菌絲體水萃物改善香菸煙霧萃取物誘導肺泡上皮A549細胞傷害之能力的結果,其中AcH(L)、AcH(M)及AcH(H)係分別指樟芝菌絲體水萃物濃度為0.25 mg/ml、0.5 mg/ml及1.0 mg/ml。Figure 1 shows the results of the water extract of Antrodia camphorata mycelium improving the ability of cigarette smoke extract to induce the injury of alveolar epithelial A549 cells, where AcH(L), AcH(M) and AcH(H) refer to Antrodia camphorata respectively The concentration of silk extracts was 0.25 mg/ml, 0.5 mg/ml and 1.0 mg/ml.
第2圖繪示樟芝菌絲體醇萃物改善香菸煙霧萃取物誘導肺泡上皮A549細胞傷害之能力的結果,其中AcMe(L)、AcMe(M)及AcMe(H)係分別指樟芝菌絲體醇萃物濃度為25 μg/ml、50 μg/ml及100 μg/ml。Figure 2 shows the results of the mycelium alcohol extract of Antrodia camphorata improving the ability of cigarette smoke extract to induce damage to alveolar epithelial A549 cells, where AcMe(L), AcMe(M) and AcMe(H) refer to Antrodia camphorata respectively Serum alcohol extract concentration was 25 μg/ml, 50 μg/ml and 100 μg/ml.
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107117897A TWI698243B (en) | 2018-05-25 | 2018-05-25 | Use of antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease |
CN201810761894.4A CN110522771A (en) | 2018-05-25 | 2018-07-12 | Antrodia camphorata mycelium active material is used to improve the purposes of chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107117897A TWI698243B (en) | 2018-05-25 | 2018-05-25 | Use of antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202003004A true TW202003004A (en) | 2020-01-16 |
TWI698243B TWI698243B (en) | 2020-07-11 |
Family
ID=68657454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107117897A TWI698243B (en) | 2018-05-25 | 2018-05-25 | Use of antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110522771A (en) |
TW (1) | TWI698243B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082015A (en) * | 2020-01-08 | 2021-07-09 | 深圳市罗湖区人民医院 | Application of genistein in preventing chronic obstructive pulmonary disease and verification method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101803528B (en) * | 2009-02-16 | 2012-02-29 | 葡萄王生技股份有限公司 | Novel cultural method of antrodia camphorata mycelium |
US9603882B2 (en) * | 2013-08-13 | 2017-03-28 | Industrial Technology Research Institute | Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells |
TWI527586B (en) * | 2013-08-13 | 2016-04-01 | 財團法人工業技術研究院 | Use of an antrodia cinnamomea (antrodia camphorata or taiwanofungus camphoratus) extract for preparing a drug for modulating th17 cells |
TWI552755B (en) * | 2015-07-09 | 2016-10-11 | Grape King Bio Ltd | A mycelia of mycelia, a method for preparing the same, a pharmaceutical composition comprising the same, and a use thereof |
-
2018
- 2018-05-25 TW TW107117897A patent/TWI698243B/en active
- 2018-07-12 CN CN201810761894.4A patent/CN110522771A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110522771A (en) | 2019-12-03 |
TWI698243B (en) | 2020-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108676730B (en) | Fermentation production process of paecilomyces hepiali Cs-4 | |
CN109337895B (en) | Production method of high-quality high-yield selenium-rich hericium erinaceus strain | |
CN109517740B (en) | Monascus purpureus mutant strain, water-soluble functional red yeast and preparation method and application thereof | |
TWI698243B (en) | Use of antrodia cinnamomea mycelia active substance for ameliorating chronic obstructive pulmonary disease | |
CN114984066B (en) | Use of Phellinus linteus for preparing compositions for improving sarcopenia | |
TW202110465A (en) | Mycelium and/or its derivative of phellinus linteus, method of manufacturing the same and use of the same for preparing composition of improving sleep | |
CN110896784A (en) | Substitute cultivation medium, substitute cultivation method and application of inonotus obliquus | |
JP7250065B2 (en) | Compositions for ameliorating sarcopenia | |
JP6789339B2 (en) | Methods and Uses of Cordyceps mycelium Active Substances for Prevention and Amelioration of Acute Lung Injury | |
Qinqin et al. | Isolation of Cordyceps ophioglossoides L2 from fruit body and optimization of fermentation conditions for its mycelial growth | |
TWI654297B (en) | Medium of solid fermentation for increasing triterpenoids content of inonotus obliquus and preparation method thereof | |
JP2022066129A (en) | Use of morchella active substances | |
TWI601818B (en) | Medium of solid fermentation for inonotus obliquus and preparation method thereof | |
CN112931044A (en) | Culture medium and culture method of raking tooth fungus with white capsule | |
KR20080070417A (en) | Mycelia and fruiting bodies of auricularia auricula-judae having hypolipidemic effect and method for preparing the same | |
CN105535035A (en) | Inonotus obliquus fermentation culture composition and preparation method thereof | |
JPH0655133B2 (en) | Method for culturing mycelium having anti-cancer effect | |
TW202026008A (en) | Method for manufacturing and the use of lignosus rhinocerus mycelia active substance for preventing and/or ameliorating lung injury | |
TWI666315B (en) | An Taiwanofungus camphoratus culture medium for increasing the fruiting bodies and triterpenoids | |
TWI755725B (en) | Bioactive components of phellinus linteus mycelia and its use in preparation of antiviral composition against enterovirus type 71 | |
TWI788083B (en) | Use of cordyceps cicadae mycelia active substance for preventing or curing macular degeneration | |
JPS63209579A (en) | Cultivation of cordyceps sinensis sacc. | |
TWI723368B (en) | Method for manufacturing and the use of paecilomyces hepiali mycelia active substance for preventing and/or ameliorating acute lung injury | |
CN115281258B (en) | Preparation method of incense ash fungus fermented tea | |
TWI687170B (en) | Method for the cultivation of cordyceps militaris |